Korro Bio Inc
KRRO12.570USD
+1.030+8.93%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
118.13MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Korro Bio Inc Unternehmen
Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.
Korro Bio Inc Informationen
BörsenkürzelKRRO
Name des UnternehmensKorro Bio Inc
IPO-datumOct 03, 2019
CEODr. Ram Aiyar, Ph.D.
Anzahl der mitarbeiter104
WertpapierartOrdinary Share
GeschäftsjahresendeOct 03
AddresseOne Kendall Square. Building 600-700
StadtCAMBRIDGE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl02139
Telefon16174681999
Websitehttps://www.korrobio.com/
BörsenkürzelKRRO
IPO-datumOct 03, 2019
CEODr. Ram Aiyar, Ph.D.
Führungskräfte von Korro Bio Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Mr. Oliver Dolan
Mr. Oliver Dolan
Principal Accounting Officer
Principal Accounting Officer
21.48K
+21482.00%
Mr. Todd Chappell
Mr. Todd Chappell
Chief Operating Officer
Chief Operating Officer
20.13K
+20132.00%
Dr. Ram Aiyar, Ph.D.
Dr. Ram Aiyar, Ph.D.
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
--
--
Dr. Jean-Francois Formela, M.D.
Dr. Jean-Francois Formela, M.D.
Independent Director
Independent Director
--
--
Mr. Timothy R. Pearson
Mr. Timothy R. Pearson
Independent Director
Independent Director
--
--
Mr. Venkat Krishnamurthy, Ph.D.
Mr. Venkat Krishnamurthy, Ph.D.
Senior Vice President - Platform
Senior Vice President - Platform
--
--
Ms. Stephanie Engels
Ms. Stephanie Engels
Senior Vice President - People and Culture
Senior Vice President - People and Culture
--
--
Dr. Rachel Meyers, Ph.D.
Dr. Rachel Meyers, Ph.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Mr. Oliver Dolan
Mr. Oliver Dolan
Principal Accounting Officer
Principal Accounting Officer
21.48K
+21482.00%
Mr. Todd Chappell
Mr. Todd Chappell
Chief Operating Officer
Chief Operating Officer
20.13K
+20132.00%
Dr. Ram Aiyar, Ph.D.
Dr. Ram Aiyar, Ph.D.
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
--
--
Dr. Jean-Francois Formela, M.D.
Dr. Jean-Francois Formela, M.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach RegionUSD
Name
Umsatz
Anteil
United States
1.09M
0.00%
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Tue, Feb 3
Aktualisiert: Tue, Feb 3
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Atlas Venture
12.08%
New Enterprise Associates (NEA)
11.58%
Lynx1 Capital Advisors LLC
7.79%
Driehaus Capital Management, LLC
7.14%
Fidelity Management & Research Company LLC
5.99%
Andere
55.43%
Aktionäre
Aktionäre
Anteil
Atlas Venture
12.08%
New Enterprise Associates (NEA)
11.58%
Lynx1 Capital Advisors LLC
7.79%
Driehaus Capital Management, LLC
7.14%
Fidelity Management & Research Company LLC
5.99%
Andere
55.43%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
51.04%
Venture Capital
24.12%
Hedge Fund
23.88%
Investment Advisor/Hedge Fund
15.43%
Corporation
5.74%
Research Firm
2.19%
Individual Investor
1.96%
Private Equity
0.34%
Bank and Trust
0.26%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
191
11.02M
117.07%
+1.11M
2025Q3
186
9.33M
99.33%
-1.07M
2025Q2
186
10.38M
110.55%
-200.85K
2025Q1
189
10.53M
112.24%
-76.97K
2024Q4
194
10.26M
109.50%
+485.90K
2024Q3
177
9.16M
98.29%
-245.98K
2024Q2
167
9.06M
97.57%
+507.87K
2024Q1
179
7.52M
93.89%
+737.20K
2023Q4
198
7.18M
91.01%
+1.51M
2023Q3
223
264.10K
35.84%
-47.15K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Atlas Venture
1.14M
12.08%
--
--
Sep 30, 2025
New Enterprise Associates (NEA)
1.09M
11.58%
--
--
Sep 30, 2025
Lynx1 Capital Advisors LLC
733.63K
7.79%
+733.63K
--
Dec 23, 2025
Driehaus Capital Management, LLC
671.98K
7.14%
+91.12K
+15.69%
Sep 30, 2025
Fidelity Management & Research Company LLC
563.68K
5.99%
-75.54K
-11.82%
Sep 30, 2025
Platanus Investment LLC
540.16K
5.74%
--
--
Apr 15, 2025
Point72 Asset Management, L.P.
531.97K
5.65%
-8.11K
-1.50%
Sep 30, 2025
The Vanguard Group, Inc.
395.66K
4.2%
+8.92K
+2.31%
Sep 30, 2025
Cormorant Asset Management, LP
465.00K
4.94%
--
--
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
iShares Micro-Cap ETF
0.05%
Avantis US Small Cap Equity ETF
0.02%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0%
SPDR Portfolio MSCI Global Stock Market ETF
0%
ProShares Hedge Replication ETF
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Russell 3000 ETF
0%
Mehr Anzeigen
iShares Micro-Cap ETF
Anteil0.05%
Avantis US Small Cap Equity ETF
Anteil0.02%
Global X Russell 2000 ETF
Anteil0.01%
Proshares Ultra Russell 2000
Anteil0.01%
ProShares UltraPro Russell2000
Anteil0%
SPDR Portfolio MSCI Global Stock Market ETF
Anteil0%
ProShares Hedge Replication ETF
Anteil0%
Invesco Dorsey Wright SmallCap Momentum ETF
Anteil0%
iShares Russell 2000 Growth ETF
Anteil0%
iShares Russell 3000 ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Datum
Ex-Dividendentag
Art
Verhältnis
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
